AHRQ plans effectiveness review of tests for breast abnormalities
This article was originally published in The Gray Sheet
Executive SummaryAgency for Healthcare Research and Quality posts for review three key questions on the comparative effectiveness of noninvasive diagnostic tests for breast abnormalities. The review will evaluate ultrasound, magnetic resonance imaging, positron emission tomography and scintimammography for the diagnosis of breast cancer in women referred for tests after a possible breast abnormality is found during routine screening. AHRQ will address key demographic risk factors and clinical risk factors, as well as other potential risk factors that could impact test accuracy. Comments on the draft questions are due May 5
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.